SelectQuote, Inc. (SLQT), a technology-enabled direct-to-consumer insurance distribution and healthcare services platform, saw its stock crater in Tuesday's session after reporting fourth-quarter and full-year fiscal 2026 results. The company, which operates three core business lines — SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life — posted revenue of $321.7 million for the quarter, down from $345.1 million a year earlier, while swinging to a net loss of $16.8 million. Shares tumbled approximately 33.33%, falling from a prior close of $0.78 to around $0.52, as the market digested both the top- and bottom-line misses and a softer-than-anticipated outlook for the coming year.
The primary catalyst behind the sharp decline was a quarterly earnings report that fell short of analyst expectations. SelectQuote's fourth-quarter revenue of $321.7 million came in below the consensus estimate of roughly $345 million, while its loss per share of $0.19 was wider than the loss of about $0.15 to $0.16 that Wall Street had modeled. The results marked a notable reversal from the prior-year period, when the company had recorded net income of $12.9 million.
For the full fiscal year 2026, revenue totaled approximately $1.6 billion with net income of $62.2 million and adjusted EBITDA of $109.1 million. However, the headline numbers were overshadowed by forward-looking commentary, as management projected fiscal 2027 revenue of $1.35 billion to $1.45 billion — well below the roughly $1.65 billion analysts had been expecting — alongside adjusted EBITDA guidance of $90 million to $115 million.
Markets tend to react more forcefully to guidance than to backward-looking results, and that dynamic was on full display in SLQT. The company's fiscal 2027 revenue outlook implied a meaningful step down from the just-completed fiscal year, a signal that investors interpreted as reflecting ongoing pressure in the Medicare Advantage distribution market. Management has repeatedly cited "turbulent" industry conditions as insurance carriers adjust benefits and optimize volumes, and the conservative forecast reinforced concerns that these headwinds could persist.
Against that backdrop, the company's Senior segment reported a 12% year-over-year decline in quarterly revenue to $72.5 million, while Healthcare Services revenue fell 10% to $193.5 million. Submitted and approved Medicare Advantage policies both declined double digits in the quarter, a trend that contributed to the cautious near-term outlook.
The magnitude of the move reflected heavy selling pressure in a thinly traded, low-priced stock, which can amplify percentage swings. SLQT has a relatively small market capitalization — roughly $139 million prior to Tuesday's decline — and its shares trade at a low nominal price, factors that tend to produce outsized volatility on catalyst-driven days. The decline pushed the stock toward the lower end of its 52-week range and below key short-term moving averages, underscoring the technical damage inflicted by the report.
The move was largely company-specific rather than a reflection of broader market weakness, as the insurance and healthcare-services sectors did not experience a comparable drawdown. Rather, the earnings-driven move represented a repricing of the stock's fundamentals following the disappointing results and reduced forward outlook.
Looking ahead, investors will focus on whether the company can deliver on its stated goal of compounding operating cash flow, which management expects to approximately double to more than $60 million in fiscal 2027, with free cash flow of around $50 million. The company also highlighted technology-enabled efficiencies expected to drive more than $30 million in annual expense savings.
Key risks remain, however. SelectQuote's reliance on a limited number of insurance carrier partners, changes in Medicare Advantage plan design and commissions, and broader regulatory developments in the health insurance market all represent potential sources of uncertainty. Traders will also watch for any analyst estimate revisions and rating changes following the guidance cut, as well as the company's progress scaling its SelectRx pharmacy and healthcare services platform during the next Medicare annual enrollment period.
For traders seeking a data-driven edge amid volatile single-stock moves, Tickeron's Trending AI Robots page offers a curated look at its strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a way to explore systematic approaches that adapt to shifting market environments. Explore the Trending AI Robots page to see which strategies are currently leading.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLQT declined for three days, in 284 of 318 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on August 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLQT as a result. In 74 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for SLQT turned negative on August 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
SLQT moved below its 50-day moving average on August 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
SLQT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 136 of 149 cases where SLQT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.234) is normal, around the industry mean (6.664). SLQT's P/E Ratio (145.000) is considerably higher than the industry average of (34.174). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.342). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.058) is also within normal values, averaging (2.968).
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. SLQT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a technology-enabled, direct-to-consumer distribution platform that provides consumers with a transparent and convenient venue to shop for complex senior health, life and auto & home insurance policies from a curated panel of insurance carriers
Industry InsuranceBrokersServices